Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.

Date publication

décembre 2015

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Brasseur M, Heurgué-Berlot A, Barbe C, Brami C, Rey JB, Vella-Boucaud J, Dabouz F, Deslée G, Grange F, Volet J, Bouché O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26694960

Résumé

Reactivation of hepatitis B or C virus can occur in patients undergoing chemotherapy. Recommendations for selective or systematic hepatitis B virus testing prior chemotherapy for solid tumors differ. The primary aim was to determine the seroprevalence of hepatitis B or C in a low endemic country. The second objective was to assess the relevance of a questionnaire on hepatitis B/C risk factors to consider a selective screening.

Mots clés

Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, France, epidemiology, Hepatitis B, diagnosis, Hepatitis C, diagnosis, Humans, Male, Middle Aged, Neoplasms, drug therapy, Prevalence, Prospective Studies, Risk Factors, Seroepidemiologic Studies, Surveys and Questionnaires, Young Adult

Référence

BMC Cancer. 2015 Dec;15:999